Neuroinflammation and Microglia Pathway in Alzheimer's Disease
Overview
Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), involving chronic activation of microglia, astrocytes, and the complement system [@heneka2015]. While neuroinflammation was originally considered a secondary response to amyloid and tau pathology, increasing evidence suggests it plays a primary role in disease progression. This page focuses on microglial-mediated neuroinflammation in AD [@wang2015].
Microglia in AD
Normal Microglial Function
Microglia are the resident immune cells of the CNS [@hansen2018]:
| Function | Mechanism | AD Relevance |
|----------|-----------|--------------|
| Surveillance | Continuous process extension | Impaired in AD |
| Phagocytosis | Clearance of debris/pathogens | Reduced in AD |
| Synaptic pruning | Complement-mediated | Excessive in AD |
| Cytokine release | Innate immune response | Dysregulated in AD |
Microglial States
Microglia adopt different activation states in AD [@keren2017]:
Homeostatic: Resting, surveilling
Disease-associated microglia (DAM): TREM2-dependent
Activated microglia: Pro-inflammatory (M1-like)
Alternative activation: Anti-inflammatory (M2-like)TREM2-Dependent Microglial Response
TREM2 Biology
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor critical for AD:
- Ligands: Aβ oligomers, lipoproteins, apoptotic cells
- Signaling: DAP12 adaptor protein
- Function: Phagocytosis, survival, cytokine production
...Neuroinflammation and Microglia Pathway in Alzheimer's Disease
Overview
Neuroinflammation is a central pathological feature of Alzheimer's disease (AD), involving chronic activation of microglia, astrocytes, and the complement system [@heneka2015]. While neuroinflammation was originally considered a secondary response to amyloid and tau pathology, increasing evidence suggests it plays a primary role in disease progression. This page focuses on microglial-mediated neuroinflammation in AD [@wang2015].
Microglia in AD
Normal Microglial Function
Microglia are the resident immune cells of the CNS [@hansen2018]:
| Function | Mechanism | AD Relevance |
|----------|-----------|--------------|
| Surveillance | Continuous process extension | Impaired in AD |
| Phagocytosis | Clearance of debris/pathogens | Reduced in AD |
| Synaptic pruning | Complement-mediated | Excessive in AD |
| Cytokine release | Innate immune response | Dysregulated in AD |
Microglial States
Microglia adopt different activation states in AD [@keren2017]:
Homeostatic: Resting, surveilling
Disease-associated microglia (DAM): TREM2-dependent
Activated microglia: Pro-inflammatory (M1-like)
Alternative activation: Anti-inflammatory (M2-like)TREM2-Dependent Microglial Response
TREM2 Biology
TREM2 (Triggering Receptor Expressed on Myeloid Cells 2) is a microglial receptor critical for AD:
- Ligands: Aβ oligomers, lipoproteins, apoptotic cells
- Signaling: DAP12 adaptor protein
- Function: Phagocytosis, survival, cytokine production
DAM (Disease-Associated Microglia)
Mermaid diagram (expand to render)
TREM2 Variants
Common AD risk variants in TREM2 [@guerreiro2013]:
- R47H: Increased AD risk (~3x)
- R62H: Modest risk increase
- D87N: Rare variant
- Y38C: Rare pathogenic
Complement System in AD
Complement Activation
The complement system is highly activated in AD:
Classical pathway:
- C1q binds to Aβ plaques
- Initiates cascade
- Generates C3a, C5a (anaphylatoxins)
Consequences:
- Microglial activation
- Synaptic elimination
- Inflammation amplification
C1q and Synaptic Pruning
C1q marks synapses for elimination:
C1q binds to vulnerable synapses
C3 activation recruits microglia
Complement receptor 3 (CR3) mediates phagocytosis
Synaptic loss in early ADInflammatory Cytokines in AD
Key Cytokines
| Cytokine | Source | Effect in AD |
|----------|--------|--------------|
| IL-1β | Microglia, astrocytes | Pro-inflammatory, drives tau pathology |
| TNF-α | Microglia | Neurotoxic, synaptic dysfunction |
| IL-6 | Various | Acute phase, cognitive decline |
| IL-10 | Anti-inflammatory | Often elevated, may be compensatory |
Cytokine Signaling Pathways
Aβ plaques → Microglial activation → NF-κB activation → Pro-inflammatory cytokine release → Neuronal dysfunction
Astrocyte Involvement
Reactive Astrocytes
Astrocytes become reactive in AD:
- A1 astrocytes: Neurotoxic, induced by IL-1α, TNF, C1q
- Loss of function: Impaired glutamate uptake, potassium buffering
- Gain of function: Pro-inflammatory cytokine release
Astrocyte-Microglial Interactions
Cross-talk between astrocytes and microglia:
Astrocyte-derived cytokines activate microglia
Microglial factors modulate astrocyte reactivity
Feedback loops amplify inflammationNeuroinflammation-Tau Interaction
Bidirectional Relationship
Tau pathology and neuroinflammation interact:
Inflammation drives tau: Cytokines promote tau phosphorylation
Tau drives inflammation: Extracellular tau activates microglia
Spread: Inflammation facilitates tau propagationMicroglial Phagocytosis of Tau
- Impaired clearance in AD
- Tau aggregates overwhelm microglia
- Failed degradation leads to inflammation
Therapeutic Approaches
Anti-Inflammatory Strategies
| Target | Approach | Agent | Status |
|--------|----------|-------|--------|
| NSAIDs | COX inhibition | Various | Failed |
| TREM2 | Agonistic antibodies | Anti-TREM2 mAbs | Phase 2 |
| IL-1β | Receptor antagonist | Anakinra | Phase 2 |
| Complement | C1q inhibition | Anti-C1q | Preclinical |
Microglial Modulation
| Strategy | Target | Status |
|----------|--------|--------|
| TREM2 activation | TREM2 | Phase 2 |
| Colony-stimulating factor 1 receptor (CSF1R) antagonism | Microglial depletion | Preclinical |
| PPARγ agonists | Anti-inflammatory | Failed |
Clinical Trials
| Trial ID | Intervention | Population | Status |
|----------|--------------|------------|--------|
| NCT01608142 | Anakinra | Mild AD | Completed |
| NCT02474948 | RG7412 (anti-TREM2) | AD | Phase 1 complete |
| NCT05618348 | Tocilizumab | Early AD | Recruiting |
| NCT04881253 | Anti-TREM2 mAb | MCI-AD | Phase 2 |
Biomarkers
Inflammatory Markers
| Marker | Fluid | Correlation |
|--------|-------|-------------|
| YKL-40 | CSF, plasma | Disease progression |
| IL-6 | CSF | Cognitive decline |
| TNF-α | CSF | Disease severity |
| C1q | CSF | Synaptic loss |
| sTREM2 | CSF | TREM2 pathway engagement |
See Also
- [TREM2 pathway](/mechanisms/trem2-microglia-pathway-alzheimers)
- [Complement system](/mechanisms/complement-system-pathway)
- [Neuroinflammation overview](/mechanisms/neuroinflammation-pathway)
- [Alzheimer's disease](/diseases/alzheimers)
- [TREM2 gene](/genes/trem2)
References
[Heneka MT, et al. Neuroinflammation in Alzheimer's disease. Lancet Neurology. 2015](https://doi.org/10.1016/S1474-4422(15)70016-5)
[Keren-Shaul N, et al. A unique microglia type associated with Alzheimer's disease. Cell. 2017](https://doi.org/10.1016/j.cell.2017.07.018)
[Guerreiro R, et al. TREM2 variants in Alzheimer's disease. New England Journal of Medicine. 2013](https://doi.org/10.1056/NEJMoa1211851)
[Wang Y, et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell. 2015](https://doi.org/10.1016/j.cell.2015.12.056)
[Sims JR, et al. TREM2 deficiency reduces neuronal and synaptic loss in an amyloid model. Nature. 2017](https://doi.org/10.1101/134551)
[Hansen DV, et al. Microglia in Alzheimer's disease. Journal of Cell Biology. 2018](https://doi.org/10.1083/jcb.201712069)From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
- [Blood-Brain Barrier SPM Shuttle System](/hypothesis/h-959a4677) — <span style="color:#81c784;font-weight:600">0.75</span> · Target: TFRC
- [Senescent Microglia Resolution via Maresins-Senolytics Combination](/hypothesis/h-3f02f222) — <span style="color:#81c784;font-weight:600">0.72</span> · Target: BCL2L1
- [Microglial Efferocytosis Enhancement via GPR32 Superagonists](/hypothesis/h-470ff83e) — <span style="color:#81c784;font-weight:600">0.63</span> · Target: CMKLR1
- [Circadian-Gated Maresin Biosynthesis Amplification](/hypothesis/h-83efeed6) — <span style="color:#81c784;font-weight:600">0.60</span> · Target: ALOX12
- [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
- [Oligodendrocyte Protectin D1 Mimetic for Myelin Resolution](/hypothesis/h-f71a9791) — <span style="color:#ffd54f;font-weight:600">0.57</span> · Target: GPR37
- [Mitochondrial SPM Synthesis Platform Engineering](/hypothesis/h-13bbfdc5) — <span style="color:#ffd54f;font-weight:600">0.47</span> · Target: ALOX5
Related Analyses:
- [Immune atlas neuroinflammation analysis in neurodegeneration](/analysis/SDA-2026-04-02-gap-immune-atlas-neuroinflam-20260402) 🔄
- [Neuroinflammation resolution mechanisms and pro-resolving mediators](/analysis/SDA-2026-04-01-gap-014) 🔄
Pathway Diagram
The following diagram shows the key molecular relationships involving Neuroinflammation and Microglia Pathway in Alzheimer's Disease discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)